Zealand Pharma A/S
  • About Zealand
    • About Us
    • Disease Focus
    • History
    • Corporate Management
    • Corporate Governance
    • Corporate Social Responsibility
    • Board of Directors
    • Videos About Zealand
    • Transparency Reporting
  • R&D
    • Our Focus
    • Product Pipeline
    • Glepaglutide for SBS
    • Dasiglucagon for BHAP Systems
    • Dasiglucagon for CHI
    • BI 456906 GLP-1/GLU Dual Agonist
    • Amylin Analogue, ZP8396
    • In-licensing
    • What are Peptides?
    • Peptide Platform Video
  • Investor
    • Investor Relations
    • Corporate Presentation
    • Stock Information
    • Shareholder Portal
    • Financial Calendar
    • Financial Reports
    • Events
    • Annual General Meeting
    • SEC Filings
    • Analyst Coverage
    • Prospectus
  • Media
    • Zealand News
    • Media Inquiry
    • Downloads
  • Careers
    • Zealand as a Workplace
    • Meet Us
    • Positions
    • Personal Data in the Recruitment Process
    • Disclaimer: Beware of Recruitment Fraud
  • Contact
  • Financial Reports
  • Financial Reports for 2022
  • Financial Reports for 2021
  • Financial Reports for 2020
  • Financial Reports for 2019
  • Financial Reports for 2018
  • Financial Reports for 2017
  • Financial Reports for 2016
  • Financial Reports for 2015
  • Financial Reports for 2014

Financial reports for 2019

Annual Report

Annual report for 2019

Interim Reports

Interim report for Q3 2019

Interim report for H1 2019

Interim report for Q1 2019

Zealand Pharma A/S     Sydmarken 11      2860 Søborg Denmark     Tel +45 88 77 36 00     info@zealandpharma.com

Legal disclaimer     Privacy policy